Dr. Andtbacka on Ongoing Trials With Oncolytic Immunotherapies in Melanoma | OncLive

Dr. Andtbacka on Ongoing Trials With Oncolytic Immunotherapies in Melanoma

February 9, 2016

Robert Andtbacka, MD, associate professor, Division of Surgical Oncology, Department of Surgery, University of Utah School of Medicine, discusses ongoing clinical trials investigating oncolytic immunotherapies as a treatment for melanoma.

Robert Andtbacka, MD, associate professor, Division of Surgical Oncology, Department of Surgery, University of Utah School of Medicine, discusses ongoing clinical trials investigating oncolytic immunotherapies as treatment for melanoma.

Oncolytic immunotherapies have been a research focus in the field of melanoma for the past few years, Andtbacka says. The agents, which are injected directly into tumors, are being investigated as both monotherapy and as part of combination regimens.

Andtbacka says oncolytic immunotherapies are also being studied in the neoadjuvant setting for patients with resectable disease.


x